分期双侧聚焦超声丘脑毁损术治疗特发性震颤的安全性和有效性:一项开放标签临床试验
这项前瞻性、开放标签、多中心试验在7个美国学术医疗中心纳入51例特发性震颤患者,评估分期双侧聚焦超声丘脑毁损术的安全性和有效性。3个月时震颤/运动评分(CRST A和B部分)从17.4改善至6.4(改善66%,95%CI 59.8-72.2,P<.001),姿势性震颤和残疾评分也显著改善。不良事件大多为轻度,12例出现轻度共济失调,6例在12个月时持续存在。
要点
- 分期双侧聚焦超声丘脑毁损术在3个月时使CRST A和B部分评分改善66%(95%CI 59.8-72.2,P<.001)。
- 12例参与者出现轻度共济失调,6例在12个月时持续存在。
- 不良事件以轻度为主(159/188,85%),包括麻木/刺痛、构音障碍、共济失调等。
核心结论
- 分期双侧聚焦超声丘脑毁损术显著降低特发性震颤患者的震颤严重程度和功能障碍评分。
- 言语、吞咽和共济失调相关不良事件大多为轻度和一过性。
研究设计与样本
- 前瞻性、开放标签、多中心试验,于2020年7月至2021年10月在美国7个学术医疗中心治疗特发性震颤患者,随访12个月。
- 62例入组患者均在入组前至少9个月接受过单侧聚焦超声丘脑毁损术,其中11例被排除,51例接受治疗。
- 纳入标准包括年龄22岁及以上、药物难治性、震颤严重程度(CRST A部分姿势性或动作性震颤评分≥2)和功能障碍(CRST C部分任一类别评分≥2)。
主要发现
- 平均(SD)人群年龄为73(13.9)岁,44例参与者(86.3%)为男性。
- 平均(SD)震颤/运动评分从17.4(5.4;95%CI 15.9-18.9)改善至3个月时的6.4(5.3;95%CI 4.9-7.9),CRST A和B部分评分改善66%(95%CI 59.8-72.2;P<.001)。
- 平均(SD)姿势性震颤从2.5(0.8;95%CI 2.3-2.7)改善至0.6(0.9;95%CI 0.3-0.8),P<.001。
- 平均(SD)残疾评分从10.3(4.7;95%CI 9.0-11.6)改善至2.2(2.8;95%CI 1.4-2.9),P<.001。
- 12例参与者出现轻度(研究定义)共济失调,其中6例在12个月时持续存在;不良事件共188例次,其中159例次(85%)为轻度、25例次(13%)为中度、1例次为重度尿路感染。
关键数值与推荐
- 主要结局指标为治疗后3个月治疗侧的震颤/运动评分(CRST A和B部分)。
- 次要评估为有效性和安全性指标,持续至12个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Unilateral magnetic resonance-guided focused ultrasound ablation of ventralis intermedius nucleus of the thalamus for essential tremor reduces tremor on 1 side, but untreated contralateral or midline symptoms remain limiting for some patients. Historically, bilateral lesioning produced unacceptable risks and was supplanted by deep brain stimulation; increasing acceptance of unilateral focused ultrasound lesioning has led to interest in a bilateral option. OBJECTIVE: To evaluate the safety and efficacy of staged, bilateral focused ultrasound thalamotomy. DESIGN, SETTING, AND PARTICIPANTS: This prospective, open-label, multicenter trial treated patients with essential tremor from July 2020 to October 2021, with a 12-month follow-up, at 7 US academic medical centers. Of 62 enrolled patients who had undergone unilateral focused ultrasound thalamotomy at least 9 months prior to enrollment, 11 were excluded and 51 were treated. Eligibility criteria included patient age (22 years and older), medication refractory, tremor severity (Clinical Rating Scale for Tremor [CRST] part A score ≥2 for postural or kinetic tremor), and functional disability (CRST part C score ≥2 in any category). INTERVENTION: A focused ultrasound system interfaced with magnetic resonance imaging allowed real-time alignment of thermography maps with anatomy. Subthreshold sonications allowed target interrogation for efficacy and off-target effects before creating an ablation. MAIN OUTCOMES AND MEASURES: Tremor/motor score (CRST parts A and B) at 3 months for the treated side after treatment was the primary outcome measure, and secondary assessments for efficacy and safety continued to 12 months. RESULTS: The mean (SD) population age was 73 (13.9) years, and 44 participants (86.3%) were male. The mean (SD) tremor/motor score improved from 17.4 (5.4; 95% CI, 15.9-18.9) to 6.4 (5.3; 95% CI, 4.9 to 7.9) at 3 months (66% improvement in CRST parts A and B scores; 95% CI, 59.8-72.2; P < .001). There was significant improvement in mean (SD) postural tremor (from 2.5 [0.8]; 95% CI, 2.3 to 2.7 to 0.6 [0.9]; 95% CI, 0.3 to 0.8; P < .001) and mean (SD) disability score (from 10.3 [4.7]; 95% CI, 9.0-11.6 to 2.2 [2.8]; 95% CI, 1.4-2.9; P < .001). Twelve participants developed mild (study-defined) ataxia, which persisted in 6 participants at 12 months. Adverse events (159 of 188 [85%] mild, 25 of 188 [13%] moderate, and 1 severe urinary tract infection) reported most commonly included numbness/tingling (n = 17 total; n = 8 at 12 months), dysarthria (n = 15 total; n = 7 at 12 months), ataxia (n = 12 total; n = 6 at 12 months), unsteadiness/imbalance (n = 10 total; n = 0 at 12 months), and taste disturbance (n = 7 total; n = 3 at 12 months). Speech difficulty, including phonation, articulation, and dysphagia, were generally mild (rated as not clinically significant, no participants with worsening in all 3 measures) and transient. CONCLUSIONS AND RELEVANCE: Staged, bilateral focused ultrasound thalamotomy significantly reduced tremor severity and functional disability scores. Adverse events for speech, swallowing, and ataxia were mostly mild and transient. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT04112381.
引用
- Kaplitt MG, Krishna V, Eisenberg HM, et al. Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor: An Open-Label Clinical Trial. JAMA Neurol. 2024. PMID: 39073822. doi:10.1001/jamaneurol.2024.2295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。